GI Cancers | Clinical

RLY-4008 Shows DCR of 100% in FGFR+ Cholangiocarcinoma

September 11, 2022

A novel FGFR inhibitor, RLY-4008, induced high response rates and encouraging durability in patients with FGFR inhibitor–naïve cholangiocarcinoma harboring an FGFR2 fusion or rearrangement, according to data from the phase 1/2 ReFocus trial presented at the 2022 ESMO Congress.

ISGIO® Seeks to Clarify Gastrointestinal Cancer Updates for the Clinic

August 31, 2022

During the Annual Meeting of the International Society of Gastrointestinal Oncology, experts in the field and investigators from pivotal studies will elucidate how these advances can be used to guide treatment, and how to choose between available treatments in specific patient populations.